The FDA released draft guidance outlining how sponsors can pursue biologics license applications (BLAs) for individualized genome editing products intended for rare genetic diseases, proposing a regulatory framework for both submission and postapproval management. In a statement accompanying the draft, FDA acting commissioner Kyle Diamantas said the approach is needed because “a one-size-fits-all approach” is not suitable for individualized therapies. The draft introduces the concept of an Individualized Feature Space (IFS), described as a set of predefined limits for the allowable variation across genome-edited components within a single BLA—potentially reducing the need for additional clinical trials as patient-specific elements vary. Jefferies characterized the guidance as constructive, pointing to a broader set of de-risking data and regulatory catalysts expected ahead; the FDA is soliciting public comment through November 27.